Acumen Pharmaceuticals (ABOS) Payables (2020 - 2026)

Acumen Pharmaceuticals has disclosed Payables across 7 years of filings, most recently posting $33.1 million for Q2 2026.

• In Q2 2026, Payables rose 1471.66% year-over-year to $33.1 million; the TTM figure through Jun 2026 stood at $33.1 million (up 1471.66% YoY), while the FY2025 annual figure was $9.3 million, up 65.0% from the prior year.
• Payables came in at $33.1 million for Q2 2026 at Acumen Pharmaceuticals, up from $15.8 million in the prior quarter.
• In the past five years, Payables ranged from a high of $33.1 million in Q2 2026 to a low of $762000.0 in Q1 2023.
• Average Payables over 5 years is $5.2 million, with a median of $2.1 million recorded in 2022.
• Year-over-year, Payables slumped 65.7% in 2025 and jumped 1471.66% in 2026.
• Over 5 years, Payables stood at $1.6 million in 2022, then decreased by 15.91% to $1.4 million in 2023, then jumped by 309.57% to $5.6 million in 2024, then soared by 65.0% to $9.3 million in 2025, then surged by 254.67% to $33.1 million in 2026.
• Per Business Quant data, the three most recent Payables figures were $33.1 million in Q2 2026, $15.8 million in Q1 2026, and $9.3 million in Q4 2025.